|Bid||13.50 x 3000|
|Ask||13.51 x 3000|
|Day's Range||13.40 - 13.52|
|52 Week Range||13.17 - 19.97|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||25.63|
|Forward Dividend & Yield||0.85 (5.05%)|
|Ex-Dividend Date||Sep 29, 2020|
|1y Target Est||21.65|
CAMBRIDGE, Mass., December 02, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the United States commercial availability of LIVTENCITY™ (maribavir), the first and only treatment for adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
Icahn Enterprises and Takeda Pharmaceutical are two intriguing hedges against sky-high inflation rates.
CAMBRIDGE, Mass., November 30, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it is enhancing its Corporate Social Responsibility (CSR) Program in the U.S., making an initial commitment of $20 million its first year supporting organizations in the U.S. to help improve equity among underrepresented communities in the areas of health, education, the environment and access to nutrition/food. Takeda also announced its current 2021 U.S. CSR Program gra